Viatris Inc. (VTRS) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Scott Andrew Smith	Chief Executive Officer & Director	5.12M	1962
Andrew Enrietti	Chief Administrative & Transformation Officer	1.94M	1985
Theodora Mistras	Executive Officer	2.19M	1982
Matthew Joseph Maletta	Chief Legal Officer	2.21M	1972
Corinne Le Goff	Chief Commercial Officer	2.33M	1965
Paul Campbell	Interim CFO, Chief Accounting Officer & Corporate Controller	3.7M	1967
Hemanth Jacob Varghese	Chief Strategy Officer	0	1976
Peter McCormick	Chief Supply Officer	0	N/A
Philippe Martin	Chief R&D Officer	0	1976
Ramkumar V. Rayapureddy	Chief Information Officer	0	N/A
William Szablewski	Head of Investor Relations & Capital Markets	0	N/A
Lara Ramsburg	Chief People & Corporate Affairs Officer	0	N/A

Name

Title

Pay

Year Born

Scott Andrew Smith

Chief Executive Officer & Director

5.12M

1962

Andrew Enrietti

Chief Administrative & Transformation Officer

1.94M

1985

Theodora Mistras

Executive Officer

2.19M

1982

Matthew Joseph Maletta

Chief Legal Officer

2.21M

1972

Corinne Le Goff

Chief Commercial Officer

2.33M

1965

Paul Campbell

Interim CFO, Chief Accounting Officer & Corporate Controller

3.7M

1967

Hemanth Jacob Varghese

Chief Strategy Officer

1976

Peter McCormick

Chief Supply Officer

N/A

Philippe Martin

Chief R&D Officer

1976

Ramkumar V. Rayapureddy

Chief Information Officer

N/A

William Szablewski

Head of Investor Relations & Capital Markets

N/A

Lara Ramsburg

Chief People & Corporate Affairs Officer

N/A

Description

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.